Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Advisory Board

Ian J. Constable, MD
Chair

Dr. Constable is Founder and Professor of Ophthalmology at the Lions Eye Institute, University of Western Australia, and is an expert in gene therapy approaches to retinal disease.


Mark S. Blumenkranz, MD

Dr. Blumenkranz is Professor and Chairman at the Byers Eye Institute at Stanford. He is a renowned expert in retinal disease and has founded several Silicon Valley startup companies.


Steven D. Schwartz, MD

Dr. Schwartz is Professor of Ophthalmology and Chief of Retina Division at the UCLA Jules Stein Eye Institute. He is a renowned expert in retinal diseases and early-stage clinical research.


Judy Gordon, DVM

Dr. Gordon is a Clinical Regulatory Consultant with extensive experience in Ophthalmology products.


Steven Butler, PhD

Dr. Butler is a Consulting Biostatistician. As an Associate Director at Genentech, he served as the lead biostatistician and development sub-team leader for Lucentis.

Avalanche Raises Additional Funding in Follow-On Financing

November 22, 2013

Avalanche announced the completion of additional financing in a round consisting of both new and existing investors. Specific details of the financing, which included both preferred stock and convertible debt, were not disclosed. “Avalanche’s BioFactoryTM platform is based on powerful technology that will help address patients suffering from blinding diseases,” said Thomas Chalberg, Avalanche’s co-founder and CEO... Read More

Read All Avalanche News